STOCK TITAN

AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 9:20 a.m. ET. Peter Griffith, CFO, and Jasper van Grunsven, SVP of Rare Disease, will take part in a fireside chat. The event will be webcast live and archived for at least 90 days.

The webcast will be available to media, investors, and the public via Amgen's Investor Relations Events Calendar and archived on Amgen's website for replay.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Key Figures

Conference time: 9:20 a.m. ET Conference date: March 11, 2026 Webcast archive period: 90 days
3 metrics
Conference time 9:20 a.m. ET Leerink Partners 2026 Global Healthcare Conference presentation time
Conference date March 11, 2026 Scheduled date of Amgen’s conference appearance
Webcast archive period 90 days Minimum replay availability for the conference webcast

Market Reality Check

Price: $367.60 Vol: Volume 1,918,827 is below...
low vol
$367.60 Last Close
Volume Volume 1,918,827 is below 20-day average 2,976,071 ahead of this conference update. low
Technical Shares at $379.27 are trading above the 200-day MA of $311.42 and within 3.07% of the 52-week high.

Peers on Argus

AMGN gained 0.6% while key peers were mixed: BMY up 1.02%, and GILD, PFE, SNY, G...

AMGN gained 0.6% while key peers were mixed: BMY up 1.02%, and GILD, PFE, SNY, GSK down between 0.33% and 0.54%, suggesting stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 24 (Neutral)
Pattern 5 events
Date Event Sentiment Move Catalyst
Feb 24 Investor conference Neutral +0.4% TD Cowen health care conference webcast and management presentation details.
Feb 13 Investor conference Neutral +1.1% Citi virtual oncology leadership summit appearance and webcast access.
Feb 03 Earnings results Positive +8.2% Q4 and 2025 results with revenue, product sales and GAAP EPS growth.
Jan 28 Earnings webcast Neutral +0.2% Scheduling and webcast details for Q4 and full-year 2025 results call.
Jan 20 Legal action Negative +0.2% Lawsuit over prescription drug access involving a large pharmaceutical company.
Pattern Detected

Recent AMGN news, including conference appearances and earnings updates, often coincided with modestly positive price reactions, with only a lawsuit headline showing divergence.

Recent Company History

This announcement continues a pattern of AMGN engaging regularly with investors through conferences and webcasts. In late February and mid-February, the company highlighted appearances at the TD Cowen and Citi oncology conferences, each followed by small positive moves. Earlier, Q4 and full-year 2025 earnings showed higher revenues and GAAP EPS, with a stronger price reaction. A prior webcast announcement and a lawsuit headline produced only mild moves. Today’s Leerink conference notice fits this cadence of ongoing investor communication atop recently reported financial strength.

Regulatory & Risk Context

Active S-3 Shelf
Shelf Active
Active S-3 Shelf Registration 2026-02-13

An automatic shelf registration filed on 2026-02-13 (Form S-3ASR) allows Amgen to issue various securities and register resale of common stock over time. The shelf is effective and has been used in at least 2 prospectus supplements dated 2026-02-17 and 2026-02-18, indicating active access to capital markets.

Market Pulse Summary

This announcement highlights Amgen’s continued engagement with the investment community through a fi...
Analysis

This announcement highlights Amgen’s continued engagement with the investment community through a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 9:20 a.m. ET. The webcast will be publicly accessible and archived for at least 90 days, similar to recent TD Cowen and Citi conference appearances. In context of strong 2025 results and an active capital-markets program, investors may track management commentary for any incremental strategic or financial color.

AI-generated analysis. Not financial advice.

THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jasper van Grunsven, senior vice president of rare disease at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. 

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen  
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. 

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.  

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.  

For more information, visit Amgen.com and follow Amgen on XLinkedInInstagramYouTubeFacebookTikTok and Threads

CONTACT: Amgen, Thousand Oaks 
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors)  

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference-302705704.html

SOURCE Amgen

FAQ

When will Amgen (AMGN) present at the Leerink Partners 2026 Global Healthcare Conference?

Amgen will present on March 11, 2026 at 9:20 a.m. ET. According to Amgen, the presentation is scheduled as a fireside chat featuring senior executives and will be webcast live for public viewing and archived for replay.

Who will represent Amgen (AMGN) in the fireside chat on March 11, 2026?

Peter Griffith (CFO) and Jasper van Grunsven (SVP, Rare Disease) will participate in the fireside chat. According to Amgen, both executives will discuss company developments during the session and answer investor-focused questions.

How can investors watch Amgen's (AMGN) Leerink 2026 presentation live or on replay?

The presentation will be webcast live and archived for replay for at least 90 days. According to Amgen, viewers can access the live webcast and archived replay via the Investor Relations Events Calendar on Amgen's website.

Will Amgen's (AMGN) Leerink 2026 webcast be available to the general public and media?

Yes, the webcast is open to media, investors, and the general public. According to Amgen, the simultaneous internet broadcast ensures public access and the archived replay will remain available for at least 90 days post-event.

Where is the archived replay of Amgen's (AMGN) March 11, 2026 presentation hosted and for how long?

The archived replay will be hosted on Amgen's website under Investors and archived for at least 90 days. According to Amgen, the replay link and event timing are listed on the Investor Relations Events Calendar.

Will Amgen (AMGN) discuss rare disease programs during the Leerink Partners 2026 fireside chat?

Yes, rare disease topics are expected given a participant's role as SVP of Rare Disease. According to Amgen, Jasper van Grunsven will participate in the fireside chat and may address developments in the rare disease portfolio.
Amgen Inc

NASDAQ:AMGN

AMGN Rankings

AMGN Latest News

AMGN Latest SEC Filings

AMGN Stock Data

204.45B
536.31M
Drug Manufacturers - General
Biological Products, (no Diagnostic Substances)
Link
United States
THOUSAND OAKS